Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
SNSE - Sensei Biotherapeutics, Inc.
Market Cap 33.20M P/E - EPS this Y 9.00% Ern Qtrly Grth -
Income -29.67M Forward P/E -0.84 EPS next Y -0.90% 50D Avg Chg -6.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -13.00%
Dividend N/A Price/Book 0.41 EPS next 5Y - 52W High Chg -45.00%
Recommedations 1.20 Quick Ratio 10.57 Shares Outstanding 25.15M 52W Low Chg 10.00%
Insider Own 34.39% ROA -27.03% Shares Float 16.51M Beta 0.02
Inst Own 8.42% ROE -45.17% Shares Shorted/Prior 250.59K/264.96K Price 1.25
Gross Margin - Profit Margin - Avg. Volume 22,724 Target Price 4.25
Oper. Margin - Earnings Date Nov 5 Volume 33,226 Change -3.85%
Healthcare | Biotechnology | United States
About Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Sensei Biotherapeutics, Inc. News
11/14/24 Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
10/29/24 Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences
10/22/24 3 US Penny Stocks To Monitor In October 2024
09/04/24 Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference
09/04/24 Sensei Biotherapeutics to Present at Upcoming Conferences
08/06/24 Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
05/30/24 Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference
05/23/24 Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101
05/09/24 Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
04/24/24 Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting
04/09/24 Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference
04/04/24 Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment
03/22/24 Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium
03/06/24 Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences
02/28/24 Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
01/04/24 Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
SNSE Chatroom

User Image StockAuthority Posted - 58 minutes from now

$SNSE 1.26 gap fill doable here.

User Image invbond Posted - 2 minutes from now

$SNSE Let’s get over $0.60 , move to $1.26 will will have a smooth sail

User Image Smesic Posted - 6 hours ago

$SNSE let’s have a great day tomorrow!

User Image Smesic Posted - 10 hours ago

$SNSE F*** $1 I want $5📈😎

User Image AtackBrrr Posted - 10 hours ago

$SNSE 1. Lead Candidate - SNS-101: Sensei’s SNS-101 is a monoclonal antibody targeting VISTA, an immune checkpoint protein. It is in Phase 1/2 trials, showing promising preclinical data and early clinical safety results. The company plans to provide further updates in late 2024, which could serve as a catalyst  . 2. Strong Analyst Support: Analysts are optimistic, with a consensus price target of $4.33, representing a significant upside from the current share price. Analysts from HC Wainwright and Citigroup have reiterated “Strong Buy” ratings  . 3. Financial Health: The company has a cash runway extending into 2025, ensuring operational stability for ongoing trials. However, as with any early-stage biotech, future funding needs remain a consideration . 4. Risks and Challenges: While SNS-101 has potential, it is still early in development. Investors should consider the inherent risks of clinical trial failures and the need for regulatory approvals

User Image DougieFreshPicks Posted - 10 hours ago

$SNSE $TRUG sounds good!!!

User Image levans80 Posted - 11 hours ago

$SNSE I would call that very nice close. Obvious big money coming in at the end

User Image StockAuthority Posted - 12 hours ago

$SNSE

User Image StockAuthority Posted - 12 hours ago

$SNSE Chart will go back to these recent swing highs, the volume last time it went to .86 was ALL TIME HIGH VOLUME. If you understand Volume Price Analysis you know why that is, and that is why I circled that bar.

User Image StockAuthority Posted - 12 hours ago

$SNSE strong buyers in AH. TOmorrow will be fun. Bio mania week this week and into next week. .86 coming soon.

User Image StockAuthority Posted - 12 hours ago

$SNSE The more I look into this the more I like it. Will be slapping hard tomorrow when spread is better. Biotech sending stocks 700% this week and analysts have a 1000% higher price target consensus!

User Image ApeTradez Posted - 13 hours ago

$SNSE $SPAI Both entries curling nicely 📈✅️ $BTCS Continuing to hold for more 🦍

User Image invbond Posted - 13 hours ago

$SNSE For biotech plays like SNSE, traditional chart analysis often falls short because these stocks are highly driven by catalysts, clinical milestones, and financial fundamentals rather than just technical patterns. With SNSE’s book value calculated at $1.86/share based on its $47m cash balance alone, it is clear that the current market price significantly undervalues the company. Such a disconnect highlights the opportunity for investors like me who recognize its potential beyond the charts. And remember, biotech plays often require a deeper look at intrinsic value and upcoming catalysts to truly assess their worth.

User Image StockAuthority Posted - 14 hours ago

$SNSE that huge bidder still there in AH, buyers stepping in again.

User Image Louis_WinthorpeIII Posted - 14 hours ago

$SNSE Different play, same game. It's Rotisserie time. Just set it and forget it! 🤣

User Image StockAuthority Posted - 14 hours ago

$MSTZ 155 in an hour, nice! And yeah I made $7000 today so far from trades on MSTR. Still have some MSTZ and also MSTR puts for tomorrow. Dont miss $SNSE too think that will go 50% up from here soon, biotech on fire.

User Image levans80 Posted - 14 hours ago

$SNSE got my fill at .4700 on the dot and lowered my avg to right around 49. It was .52

User Image graballucan Posted - 15 hours ago

$SNSE What’s it looking like?

User Image StockAuthority Posted - 15 hours ago

$SNSE here today, gone tomorrow.

User Image Acecat Posted - 15 hours ago

$SNSE People need to get a clue. Look at the three month chart and deal with reality.

User Image Garymoved Posted - 15 hours ago

$SNSE

User Image StockAuthority Posted - 15 hours ago

$SNSE welcome to POWER HOUR! Slap That Ask... biotech is the place to be as we saw with $HCWB running 700% this week... surely 125% to get the gap fil at 1.26 isnt too much to ask. especially when analyst estimates are for 1000% higher. In $DRUG bio momo we trust. Amen.

User Image levans80 Posted - 15 hours ago

$SNSE have a bid for about 1100 shares just a few cents away.

User Image StockAuthority Posted - 15 hours ago

$SNSE I could see this easily hitting .60s by end of power hour/ after hours.

User Image Grelada Posted - 16 hours ago

$SNSE

User Image StockAuthority Posted - 17 hours ago

$SNSE Who is ready for .86 first target??? I know I am!!!

User Image graballucan Posted - 17 hours ago

$SNSE Lunch over, let’s go!

User Image StockAuthority Posted - 17 hours ago

$SNSE analyst targets 1000% higher. Bids are huge.

User Image FutureIsOurs5 Posted - 18 hours ago

$SNSE needs more volume

User Image Smesic Posted - 18 hours ago

$SNSE

Analyst Ratings
HC Wainwright & Co. Buy Aug 7, 24
HC Wainwright & Co. Buy May 24, 24
Stephens & Co. Overweight May 24, 24
Stephens & Co. Overweight May 14, 24
HC Wainwright & Co. Buy Dec 4, 23
Citigroup Buy Dec 13, 22
Oppenheimer Outperform Oct 3, 22
Piper Sandler Overweight Mar 10, 22
Berenberg Hold Jul 1, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Apeiron Investment Group Ltd. 10% Owner 10% Owner Feb 23 Buy 1.61 2,200 3,542 2,485,923 02/27/23
Peyer James Director Director Mar 02 Buy 3.20 1,203 3,850 5,231,488 06/10/22
Cambrian BioPharma Inc 10% Owner 10% Owner Mar 02 Buy 3.20 1,203 3,850 5,231,488 06/10/22
Peyer James Director Director Feb 28 Buy 3.6 2,500 9,000 5,230,786 03/01/22
Cambrian BioPharma Inc 10% Owner 10% Owner Feb 28 Buy 3.6 2,500 9,000 5,230,786 03/01/22
Peyer James Director Director Feb 25 Buy 3.65 2,500 9,125 5,228,286 02/28/22
Cambrian BioPharma Inc 10% Owner 10% Owner Feb 23 Buy 3.72 17,500 65,100 5,225,786 02/24/22
Peyer James Director Director Feb 23 Buy 3.72 17,500 65,100 5,225,786 02/24/22
Peyer James Director Director Feb 17 Buy 4.07 19,949 81,192 5,208,286 02/22/22
Cambrian BioPharma Inc 10% Owner 10% Owner Feb 17 Buy 4.07 19,949 81,192 5,208,286 02/22/22
Cambrian BioPharma Inc 10% Owner 10% Owner Feb 14 Buy 4.22 12,551 52,965 5,188,337 02/16/22
Peyer James Director Director Feb 14 Buy 4.22 12,551 52,965 5,188,337 02/16/22
Peyer James Director Director Feb 10 Buy 4.49 17,500 78,575 5,175,786 02/14/22
Cambrian BioPharma Inc 10% Owner 10% Owner Feb 11 Buy 4.49 17,500 78,575 5,175,786 02/14/22
Cambrian BioPharma Inc 10% Owner 10% Owner Feb 03 Buy 4.48 30,000 134,400 5,158,286 02/08/22
Peyer James Director Director Feb 03 Buy 4.48 30,000 134,400 5,158,286 02/08/22
Cambrian BioPharma Inc 10% Owner 10% Owner Jan 27 Buy 4.27 15,000 64,050 5,128,286 01/31/22
Peyer James Director Director Jan 27 Buy 4.27 15,000 64,050 5,128,286 01/31/22
Peyer James Director Director Jan 25 Buy 4.74 50,000 237,000 5,113,286 01/27/22
Cambrian BioPharma Inc 10% Owner 10% Owner Jan 25 Buy 4.74 50,000 237,000 5,113,286 01/27/22
Peyer James Director Director Jan 21 Buy 4.82 47,410 228,516 5,063,286 01/25/22
Cambrian BioPharma Inc 10% Owner 10% Owner Jan 21 Buy 4.82 47,410 228,516 5,063,286 01/25/22
Peyer James Director Director Jan 19 Buy 5.07 30,244 153,337 5,015,876 01/21/22
Cambrian BioPharma Inc 10% Owner 10% Owner Jan 19 Buy 5.07 30,244 153,337 5,015,876 01/21/22
Peyer James Director Director Jan 18 Buy 5.08 10,000 50,800 4,985,632 01/20/22
Cambrian BioPharma Inc 10% Owner 10% Owner Jan 18 Buy 5.08 10,000 50,800 4,985,632 01/20/22
Peyer James Director Director Jan 13 Buy 5.06 26,172 132,430 4,975,632 01/18/22
Cambrian BioPharma Inc 10% Owner 10% Owner Jan 13 Buy 5.06 26,172 132,430 4,975,632 01/18/22
Peyer James Director Director Jan 11 Buy 5.2 20,047 104,244 4,949,460 01/13/22
Cambrian BioPharma Inc 10% Owner 10% Owner Jan 11 Buy 5.2 20,047 104,244 4,949,460 01/13/22